Zdrowie i gospodarka · 23/03/2023

FDA Establishes Public Docket for Comments on Third-Party Vendor Changes for Risk Evaluation and Mitigation Strategies

The FDA is soliciting public comments on factors to consider when reviewing modification requests from drug sponsors related to changes in third-party vendors for REMS strategies, following the establishment of a new public docket.